Paragon Bioservices is a private-equity backed contract development and manufacturing organization whose focus is the development and manufacturing of biopharmaceuticals – including the production of monoclonal antibodies, recombinant proteins, viral vectors and vaccines. The company provides research services, process development and cGMP manufacturing. Paragon's cGMP facilities include microbial and mammalian suites, fill-finish and fully segregated virus facilities.
Paragon’s responsibility to their clients, a passion for science and their collective need to contribute to better public health keep them motivated and excited about the work they perform. They are driven by a commitment to provide exceptional quality, scientific excellence and superior customer service.
With 25 years in the business, Paragon’s multidisciplinary team of scientists, engineers, quality systems personnel and project managers have many years of experience working with biologics – from research and process development services to GMP manufacturing for clinical trials and eventually commercial launch.
History of Success
In 2016, Paragon received the “CMO Leadership Awards” for quality and reliability from Life Science Leader magazine. This is the fifth consecutive year that Paragon has won this award that is based on surveys received from 10,000 mid-level pharmaceutical executives. In addition, Paragon has received the “Global Supplier Award” from Eli Lilly and their Elanco Animal Health division – as well as Pfizer’s “External Research Award.” Paragon currently has multiple on-going government contracts that include the U.S. Army, National Institute of Health (NIH) and the Department of Defense.
As Paragon moved into GMP Manufacturing, won government biodefence contract and developed a Virus Facility and BSL-3 labs, they were able to collaborate with the world-renowned Dr. Myron Levine from the Center for Vaccine Development.
In 2011, Paragon also had the opportunity to work with Dr. Curt Civin—a pioneer in cancer research and stem cell transplantation—at the University of Maryland’s Center for Stem Cell Biology and Regenerative Medicine. Together with Paragon, the university developed a Stem Cell Technology Consortium.
Currently, Paragon is the largest employer at the 801 W. Baltimore property. Since moving from John Hopkins Bayview Medical Center in 2009, Paragon has created 98 new jobs and expects to create an additional 80 to 100 new positions over the next three years. As space becomes available within the BioPark, Paragon plans to continue to expand their operation. *
“Both Wexford and the executives at the BioPark have been extremely helpful and supportive since we have relocated to the BioPark. We could have never gotten this far without their support and generosity,” said Marco Chacón, Ph.D., Founder and Chairman of Paragon.
* Source: American Communities Trust, UMB2 Community Impact Report, October 2015
“The BioPark offered many unique services and amenities for Paragon’s employees—such as a café for lunches and The Smith School of Business (for employees who were working on their MBA’s or interested in continuing.”
- Marco A. Chacón, Ph.D., Founder and Chairman